Clinical Trial

Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2025 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, randomized controlled study. The study plans to enroll 414 subjects with Helicobacter pylori infection, who will be randomly assigned to the experimental group (Keverprazan dual therapy for 10 days or Keverprazan dual therapy for 14 days) or the control group (Rabeprazole quadruple therapy for 14 days) at a ratio of 1:1:1.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07122024
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Helicobacter Pylori
Enrollment 414 participants
Start Date 2024-02-19
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-14